Study suggests inhaled technosphere insulin could be considered as an option for adults with type 1 diabetes
A study in the journal Diabetes Technology & Therapeutics (DTT) concludes that inhaled technosphere insulin (TI-Afrezza) ...
pharmaphorum3d
Novo Nordisk’s diabetes treatments approved in EU
Ryzodeg (insulin degludec / insulin aspart) contains the new-generation once-daily basal insulin degludec in a soluble formulation with insulin aspart. Both of these products will be available in ...
pharmaphorum2d
Sanofi turns the tables on Lilly with biosimilar fast-acting insulin
Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...
EurekAlert!6d
Evaluation of inhaled technosphere insulin plus insulin degludec for adults with type 1 diabetes
A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) concluded that inhaled technosphere insulin ...
Healio4d
Inhaled insulin lowers HbA1c at 30 weeks in adults with type 1 diabetes
Technosphere insulin, a rapid-acting human insulin administrated through an inhaler, was associated with reductions in HbA1c ...
Automated insulin delivery improves glycemic control of type 2 diabetes in randomized trial
Jaeb Center for Health Research conducted a randomized controlled trial evaluating the impact of automated insulin delivery ...
Medscape6d
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ...
Medscape2d
How Does Type 1 Diabetes Develop?
Despite decades of acknowledging that a loss of insulin-producing pancreatic β-cells is central to the disorder now referred to as type 1 diabetes, the specific roles for genetic susceptibility ...